However, despite the early introduction of bioengineered tissue products, the market has been very slow to develop. It certainly did not live up to the earlier expectation of being worth US$2 billion by 2002 (1) .
A number of biomaterials based medical products have proved successful, ranging from resorbable sutures through to resorbable materials based wound dressings, e.g. Johnson & Johnson's Integra. However, such products only loosely fall under the fi eld of regenerative medicine.
Few bioengineered live tissue products have emerged onto the market despite two decades of activity. Apligraf ® (Organogenesis/ Norvatis) and Dermagraft ® (Advanced Tissue Sciences/Smith & Nephew) are products bioengineered from cells derived from neonatal foreskin and they are recommended for the treatment of chronic wounds. The use of allogenic cells in the Dermagraft ® product means that a large quantity of tissue can be engineered from a single cell source. However, even so, Smith & Nephew has recently made announcements on the limited commercial viability of the Dermagraft ® product. The cost of goods incurred in the production of the Dermagraft ® product outweigh the commercial returns in the indications for which it has been approved.
Commercializing Regenerative
Medicine Technologies: Achieving Scale in China?
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• cultured autologous epithelial cells from skin (Epicel® /CellTran's skin & C3's CellSpray® XP) as treatments for life-threatening burns and chronic wounds.
• cultured autologous chondrocytes from articular cartilage (Carticel®) as treatment for focal defects in articular cartilage of the knee. This autologous cell expansion service approach, pioneered by Genzyme Biosurgery carries a number of disadvantages; the most critical being the signifi cant turnaround time (weeks) in providing product for treatment, the high cost when compared to conventional treatments and the inadequate level of clinical benefi t to justify the cost and use in anything but life-threatening situations.
A number of clinical and commercial organizations are currently testing the application of autologous stem cell therapies in the treatment of cardiac diseases. Stem cells isolated from the patient's own bone marrow, or peripheral blood, are purifi ed and/or expanded, and injected back into the patients myocardium or coronary artery. Although there have been limited controlled studies carried out to date, the evidence suggests a clinical improvement in those patients treated, with improved heart function and perceived patient well being.
Autolgous cell therapies, however, remain a patient specifi c treatment with the cells isolated and readministered at the point of care using well established medical equipment and consumables. Whilst a number of commercial organizations, e.g. TheraVitae, Aastrom, Pluristem, etc, have developed proprietary cell manipulation or expansion procedures with a view to developing a patent protected share of the autolgous cell therapy market, it is not yet clear whether such a business model will prove sustainable in the longer term.
The promise of regenerative medicine has therefore been forestalled by both the technical challenges in developing effective products, and also by the lack of standardized, regulated, large scale manufacturing capabilities to support commercialization. Whilst more than 180 companies in the US and EU are continuing to develop therapeutic approaches using regenerative medicine technologies (2) , the production of such products on a large scale will have to be resolved for these to provide the expected impact in both patient benefi t and commercial returns.
A more attractive approach to developing commercially viable products using regenerative medicine technologies would involve the production of a standard 'offthe-shelf' product akin to that produced in traditional pharmaceutical development. Such products may be possible using embryonic stem cells, which have the ability to differentiate into any cell type in the body and the potential to be expanded indefi nitely.
Recent publications have demonstrated some critical attributes of human embryonic stem (hES) cell derived therapies:
• Geron (www.geron.com) have demonstrated preclinical effi cacy of hES cell derived cardiomyocytes in an infarcted rat heart-the cells survive, engraft and prevent heart failure.
• A study by Drukker et al (3), has shown that hES cells invoke a weaker immune response to that seen with established organ transplants, i.e., allogeneic hES cell derived treatments may only require a low level of immune supression to prevent rejection.
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• A study by Taylor et al (4) , has suggested that a panel of just 10 highly selected homozygous HLA-typed hES cell lines would be suffi cient to treat over 80% of the population when used in conjunction with traditional immuno-suppressive drugs.
The potential development of allogeneic treatments derived from hES cells opens up the possibility for the large scale manufacturing of a core 'raw material' central to a broad range of therapeutic treatments. Table 1 provides a simple overview of the challenges faced by regenerative medicine companies developing products based on stem cell therapies that require a low level of cell expansion to achieve the dosage of cells required to provide a therapeutic effect.
Scaling up Stem Cell Therapy Production
The numbers in the Table are based on expansion culture using traditional 2D approaches:
• Dosage-average dosage range used per patient in published studies (e.g.
Genzyme MAGIC clinical trial).
• Starting Cell Number-based on typical frozen stocks of mouse and human ES cells; and,
• Expansion rates-average expansion rates for mouse ES cells (hES cells are often much slower to grow in vitro) based on culture in T75 fl asks (standard 75cm 2 2D culture fl asks).
Table 1-2D Expansion of ES Cell Based Therapy
Even such a simple look at the logistics of producing larger numbers of cells required for cell therapies tells us that current approaches aren't practical or economical. The numbers of 2D culture fl asks required to produce suffi cient cells coupled with the daily feeding requirements make such an approach logistically impossible on a large scale. In addition, the cost of employing suffi cient numbers of highly skilled laboratory technicians to staff such a production facility would be prohibitive.
If we exploit the potential of stem cells and develop therapeutic treatments to treat such widespread conditions such as lung disease, we will need to re-invent the way stem cells are produced. If we cannot achieve the scale of stem cell production then stem cell based therapies can only be a specialist, high cost treatment available to a small percentage of patients. A manufacturing base akin to that currently in existence to support the mass production of small molecules in the pharmaceutical industry is required if the commercial potential of stem cell therapies is to be realized. Respiratory diseases represent a group of indications which may one day be treated through the provision of cell-based therapies to regenerate lung tissue and improve lung function. In the UK, over 30,000 people die annually from chronic obstructive pulmonary disease ('smoker's lung') and in the US over 750,000 people die annually from a form of lung disease, with the incidence across the world increasing. The scale and severity of such diseases represent a challenge not only in developing effective treatments, but in providing such treatments at a scale to match disease incidence.
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An alternative approach to stem cell production can be achieved using bioreactor technology. Scientists at NovaThera are working towards a system, the TheraMachine™, for the production of hES cells that can be standardized, automated and also removes the labor intensive elements associated with 2D cell culture. The system enables the culture of hES cells in the absence of feeder cells and using simplifi ed chemically defi ned culture media. Table 2 demonstrates the potential of such a system. • Option 1 represents the culture of a specifi c cell dosage for each patient using an individual bioreactor for each patient.
• Option 2 represents the production of a bulk dosage in one bioreactor to treat 100 patients.
The use of an automated system with reduced labor requirements provides a number of feasible approaches to the production of the required numbers of stem cells to support the production of a defi ned stem cell therapeutic.
The NovaThera approach would enable the large scale production of hES cells to the required regulatory standard. hES cells produced in this way would become the key raw material to be used in stem cell therapies developed by third party institutions and commercial organizations. www.novathera.com
